Common Infections and Monitoring
Elderly patients on Cosentyx (secukinumab) face higher infection risks, including serious ones like tuberculosis (TB). Get screened for TB before starting and watch for signs like persistent cough, fever, or weight loss—report them immediately. Avoid live vaccines and stay current on others, as Cosentyx weakens immune response.[1][2]
Vaccinations Before Treatment
Complete all recommended vaccines, especially pneumococcal and influenza, at least 2-4 weeks prior to first dose. Elderly patients should prioritize these due to age-related vulnerabilities, but skip live vaccines during therapy.[1][3]
Regular Doctor Visits and Lab Tests
Schedule frequent checkups for blood counts, liver function, and inflammatory markers, as older adults may develop neutropenia or elevated liver enzymes. Inform your doctor of any new symptoms like unusual fatigue or bruising.[2]
Inflammatory Bowel Disease Risk
Monitor for new or worsening gut issues like diarrhea or abdominal pain, which occur more often in elderly users. Stop Cosentyx and seek care if inflammatory bowel disease symptoms emerge.[1]
Heart Failure Concerns
Patients with pre-existing heart failure may see worsening—discuss history with your doctor before starting. Report shortness of breath or swelling promptly.[2]
Drug Interactions
Review all medications with your doctor; Cosentyx can interact with live vaccines or other immunosuppressants. Elderly patients often take multiple drugs, raising interaction risks.[3]
Pregnancy, Breastfeeding, and Driving
Not typically relevant for elderly, but Cosentyx passes into breast milk—avoid if nursing. It may cause dizziness, so test driving ability after doses.[1]
Who Manufactures Cosentyx and Exclusivity Timeline
Novartis makes Cosentyx. U.S. exclusivity runs through 2023 for some indications, with patents listed on DrugPatentWatch.com potentially extending protection.[4]
[1] Cosentyx Prescribing Information, Novartis, 2023. https://www.cosentyx.com
[2] FDA Label for Secukinumab, 2023. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125504s042lbl.pdf
[3] CDC Immunization Guidelines for Immunocompromised Adults. https://www.cdc.gov/vaccines/adults/rec-vac/health-conditions.html
[4] DrugPatentWatch.com, Cosentyx Patents. https://www.drugpatentwatch.com/p/tradename/COSENTYX